Clinical characteristics and prostate-cancer-specific mortality of competitive risk nomogram in the second primary prostate cancer

Xu, Chaojie; Pei, Dongchen; Liu, Yi; Guo, Jianhua; Liu, Nan; Wang, Qian; Yu, Yang; Kang, Zhengjun

doi:10.3389/fonc.2023.918324

Cited by 3 publications

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Unraveling the role of adjuvant chemotherapy in elderly triple-negative breast cancer: Insights from competing risk analysis using SEER data

Ziqiang,

Tingting,

Yangyang

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Triple-negative breast cancer (TNBC) is an aggressive subtype with poor outcomes, particularly in elderly patients. Chemotherapy remains the primary systemic treatment, but its effectiveness in TNBC patients aged 70 years and older remains controversial due to comorbidities and poor treatment tolerance. This study evaluates the survival impact of adjuvant chemotherapy in this population using a competing risk analysis. Methods A retrospective cohort of 4,855 elderly TNBC patients (≥70 years) was extracted from the SEER database (1995–2016). Propensity score matching (PSM) was applied to balance baseline characteristics between chemotherapy and non-chemotherapy groups. Overall survival (OS), cancer-specific survival (CSS), and competing risks of cancer-specific death (CSD) and other-cause death (OCD) were analyzed using Kaplan-Meier and Fine-Gray subdistribution proportional hazards models. A competing risk-based nomogram was developed to predict individualized survival outcomes. Results After PSM, the chemotherapy group showed significantly improved OS (p < 0.05), but no significant difference in 5-year CSD (16.88% vs. 19.01%, p = 0.1664). However, chemotherapy reduced the 5-year cumulative incidence of OCD (8.93% vs. 18.55%, p < 0.001). Multivariate competing risk analysis identified marital status, tumor grade, receipt of radiation therapy, T stage, and N stage as independent predictors of CSD. The nomogram incorporating these factors demonstrated high predictive accuracy (AUC: 1-year = 0.788, 3-year = 0.768, 5-year = 0.747) and excellent calibration. Conclusion Adjuvant chemotherapy provides limited direct benefit in reducing CSD but significantly decreases OCD in elderly TNBC patients, improving OS. The competing risk analysis offers a comprehensive understanding of mortality risks and underscores the value of individualized treatment. The validated nomogram supports precision medicine approaches for this high-risk population. Future studies should address underlying biological mechanisms and validate findings in multi-regional cohorts.

show abstract

Unraveling the role of adjuvant chemotherapy in elderly triple-negative breast cancer: Insights from competing risk analysis using SEER data

Ziqiang,

Tingting,

Yangyang

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Identifying Key Genes as Progression Indicators of Prostate Cancer with Castration Resistance Based on Dynamic Network Biomarker Algorithm and Weighted Gene Correlation Network Analysis

Liu,

Hu,

Liu

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Background: Androgen deprivation therapy (ADT) is the mainstay of treatment for prostate cancer, yet dynamic molecular changes from hormone-sensitive to castration-resistant states in patients treated with ADT remain unclear. Methods: In this study, we combined the dynamic network biomarker (DNB) method and the weighted gene co-expression network analysis (WGCNA) to identify key genes associated with the progression to a castration-resistant state in prostate cancer via the integration of single-cell and bulk RNA sequencing data. Based on the gene expression profiles of CRPC in the GEO dataset, the DNB method was used to clarify the condition of epithelial cells and find out the most significant transition signal DNB modules and genes included. Then, we calculated gene modules associated with the clinical phenotype stage based on the WGCNA. IHC was conducted to validate the expression of the key genes in CRPC and primary PCa patients Results:Nomograms, calibration plots, and ROC curves were applied to evaluate the good prognostic accuracy of the risk prediction model. Results: By combining single-cell RNA sequence data and bulk RNA sequence data, we identified a set of DNBs, whose roles involved in androgen-associated activities indicated the signals of a prostate cancer cell transition from an androgen-dependent state to a castration-resistant state. In addition, a risk prediction model including the risk score of four key genes (SCD, NARS2, ALDH1A1, and NFXL1) and other clinical–pathological characteristics was constructed and verified to be able to reasonably predict the prognosis of patients receiving ADT. Conclusions: In summary, four key genes from DNBs were identified as potential diagnostic markers for patients treated with ADT and a risk score-based nomogram will facilitate precise prognosis prediction and individualized therapeutic interventions of CRPC.

show abstract

Incidence and Characteristics of Multiple Primary Cancers: A 20-Year Retrospective Study of a Single Cancer Center in Korea

Kwon,

Kim,

Lee

et al. 2024

Cancers

View full text Add to dashboard Cite

Rising cancer survival rates have led to an increased risk of multiple primary cancers (MPCs). Data on MPCs in South Korea are limited. This study aimed to address incidence and clinical characteristics of MPCs in a single cancer center in Korea during a 20-year period. We retrospectively analyzed 96,174 cancer patients at the Korea Cancer Center Hospital between 2003 and 2022, identifying 2167 patients with metachronous MPCs based on Surveillance, Epidemiology, and End Results SEER criteria. We categorized patients by cancer type (15 major solid cancer groups and 3 major hematologic cancer groups), including pathological diagnosis, assessed latency periods, and relative risks (RRs) for developing MPCs. The overall MPC incidence was 2.3%. Breast cancer (15.7%) was the most common primary cancer, and lung cancer (15.2%) was the most frequent second primary cancer. The median latency period for second primary cancers was 4.1 years. Decreasing latency periods for third and fourth primary cancers were observed (2.1 years and 1.6 years, respectively). Most cancers maintained their dominant pathological type despite notable changes in the prevalence of specific pathologies for certain types of second primaries. Lymphoma showed the highest RR (2.1) for developing MPCs. Significant associations were found between specific primary and subsequent cancers, including breast–ovary, thyroid–breast, stomach–pancreas, colorectal–head and neck, lung–prostate, and lymphoma–myeloid neoplasms. These findings contribute to a better understanding of MPC occurrence. They can inform future research on their etiology and development of improved management strategies.

show abstract

Clinical characteristics and prostate-cancer-specific mortality of competitive risk nomogram in the second primary prostate cancer

Cited by 3 publications

References 33 publications

Unraveling the role of adjuvant chemotherapy in elderly triple-negative breast cancer: Insights from competing risk analysis using SEER data

Unraveling the role of adjuvant chemotherapy in elderly triple-negative breast cancer: Insights from competing risk analysis using SEER data

Identifying Key Genes as Progression Indicators of Prostate Cancer with Castration Resistance Based on Dynamic Network Biomarker Algorithm and Weighted Gene Correlation Network Analysis

Incidence and Characteristics of Multiple Primary Cancers: A 20-Year Retrospective Study of a Single Cancer Center in Korea

Contact Info

Product

Resources

About